ArticleDermatology practical & conceptual2025

Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study.

Antonella Di Cesare et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.